Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Vietnamese)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

2006 AVAC Report: AIDS Vaccines: The Next Frontiers

In this report, AVAC offers its first contribution to the scenario planning critical to the success of the field. The next several years bring a variety of scenarios which cannot be encountered unprepared. Instead, the AIDS vaccine field, and the field of prevention research in general, must engage in rigorous debate, dialogue and scenario planning which anticipates the issues that the next few years will bring, and ensures that the wide range of stakeholders are informed and empowered to make decisions to compete against the virus. In this report, four thought-provoking chapters are presented, each of which begins with a future scenario that considers how the world might look in five or six or ten years’ time.

GPP Circles Diagram

The Circle Diagram tool is a four-page facilitator’s guide for an exercise designed to help participants raise and explore priority issues for HIV prevention research. It can be used to help define linkages between different issues and build support for a specific research project or trial. This is designed as a companion tool to the GPP Blueprint, a comprehensive guide for developing a stakeholder engagement plan. 

Community Mapping Tool

This tool walks trial teams through a step-by-step process for mapping where individuals who may be engaged in research live, work and access services. This is designed as a companion tool to the GPP Blueprint, a comprehensive guide for developing a stakeholder engagement plan.

GPP Strengths and Gaps

GPP Strengths and Gaps is a facilitator’s guide for an exercise that is designed to help evaluate GPP implementation at a site level. It can be used with community and trial participants to garner honest feedback and constructive suggestions for improvements. 

GPP Listing, Scoring, Ranking

This nine-page tool is a facilitator’s guide for an exercise developed by the site staff of the Microbicide Development Program in Tanzania. The activity can be used to engage community members, trial participants or staff members. It uses various participatory approaches to encourage participants to share their issues and concerns, debate amongst themselves and identify priority actions for the research site. This is designed as a companion tool to the GPP Blueprint, a comprehensive guide for developing a stakeholder engagement plan.

GPP Summary Sheets

The GPP Summary Sheets offer an at-a-glance look at the GPP guidelines for individuals who may not be primarily responsible for implementing GPP, but who need to understand them. They are organized according to the stages of the trial life cycle: planning, trial conduct and post-trial. Each stage outlines GPP topic areas, highlights key practices, and lists considerations for various stakeholders.

Stakeholder Interview Questions

The Stakeholder Interview Questions is a tool that is designed for trial site staff. It guides members of the research team through the process of conducting a one-on-one interview with a stakeholder. The tool provides guidance for talking with many different types of stakeholders. It can be used to evaluate the impact of stakeholder engagement efforts.

Px Wire April-June 2012, Vol. 5, No. 2

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights from this issue include a newly debuted research timeline: “ARV-based Prevention for HIV Negative Adults.” The timeline charts the time-to-approval trajectory, showing efficacy trials, related confirmatory studies and dates of possible regulatory submission for a range of prevention options including oral PrEP with TDF, oral PrEP with TDF/FTC, vaginal and rectal formulations of tenofovir gel and the dapivirine-containing vaginal ring.

Px Wire January-March 2012, Vol. 5, No. 1

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue identifies ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).